In NCI-H1975 xenografts, a single 125 mg/kg intravenous dose reduced EGFR staining at 24 hours and decreased proliferation while increasing apoptosis at 24–48 hours. Recovery of the proliferation and apoptosis readouts was evident at 72 hours, limiting claims of sustained activity from a single dose. [1]
At the tested 25 mg/kg intravenous regimen, ganetespib preferentially suppressed USP22-deficient HCT116 xenografts, whereas USP22-proficient tumors showed little growth response. Untreated USP22-deficient tumors grew faster, underscoring that the observed drug response depends on genotype and treatment conditions. [2]
Transient pharmacodynamic response in NCI-H1975 xenografts
Animal study · Female 7–8-week-old C.B-17 SCID mice bearing subcutaneous NCI-H1975 xenografts (EGFR L858R/T790M) [1]
A single intravenous dose reduced EGFR staining at 24 h, with reduced BrdU incorporation and increased TUNEL staining at 24–48 h. These proliferation/apoptosis effects showed recovery at 72 h. EGFR staining was not significantly decreased at 6 h.
Conditions shared by the study groups
- Route
- Intravenous
- Frequency
- Once
- Treatment course
- Single dose, followed for up to 72 h
- Vehicle
- 10/18 DRD: 10% DMSO, 18% Cremophor RH40, 3.6% dextrose, 68.4% water
- Single-dose ganetespib
- Model: NCI-H1975 xenografts in C.B-17 SCID mice
- Reported limits: N = 8/group as captioned; exact time-point allocation unclear.
Methods and source locations
Compound reported in the paper: Ganetespib (STA-9090); Compound label in the paper: ganetespib
Findings apply to the named tested material and experimental model; they do not establish identity, purity or performance of a current A11402 lot.
Fig. 4A–B and caption; Xenograft immunohistochemistry and image analysis; Establishment and treatment of xenografts; corresponding Results paragraph
Tumor EGFR staining: EGFR immunohistochemistry; N = 8/group as captioned; error bars + SEM — Fig. 4A and corresponding Results paragraph
Tumor proliferation and apoptosis: Multicolor tumor-section imaging; N = 8/group as captioned; error bars + SEM — Fig. 4B and corresponding Results paragraph
Single-dose ganetespib · Fig. 4A–B and caption; dedicated xenograft IHC methods; general xenograft formulation methods
USP22-dependent response of HCT116 xenografts
Animal study · Immunodeficient SCID mice bearing HCT116 USP22+/+ and USP22−/− subcutaneous xenografts; the methods place the two genotypes in opposite flanks [2]
Ganetespib had little effect on USP22-proficient tumors but preferentially suppressed the more rapid growth of USP22-deficient tumors. Ki67 staining also decreased in treated USP22-deficient tumors. The authors report >70% growth impairment in the deficient tumors and a size 50% smaller than treated wild-type tumors.
Conditions shared by the study groups
- Route
- Intravenous
- Frequency
- Daily on three consecutive days, four-day break, then three further daily doses
- Treatment course
- Two three-day treatment blocks; tumors followed through day 23 in Fig. 5
- Vehicle
- 10% DMSO (v/v), 20% Cremophor RH40 (v/v), 5% dextrose (w/v)
- Ganetespib, both USP22 genotypes
- Model: HCT116 USP22+/+ and USP22−/− xenografts in SCID mice
- Reported limits: n = 6 per group as reported. No inference of independent animals from bilateral tumor number; sex/age/SCID substrain not stated in the adopted methods.
Methods and source locations
Compound reported in the paper: Ganetespib (STA-9090); Compound label in the paper: ganetespib
Findings apply to the named tested material and experimental model; they do not establish identity, purity or performance of a current A11402 lot.
Fig. 5a–e and caption; Xenograft experiments; Statistical analyses; Results: USP22-deficient tumor cells display increased sensitivity to HSP90 inhibition
Xenograft growth by USP22 genotype: Tumor monitoring; n = 6 per group as reported; mean ± SEM, Student’s t-test in Fig. 5a–b — Fig. 5a–c and Results: USP22-deficient tumor cells display increased sensitivity to HSP90 inhibition
Ki67-positive tumor cells: Ki67 immunohistochemistry; mean ± SEM, one-way ANOVA — Fig. 5d–e and caption
Ganetespib, both USP22 genotypes · Xenograft experiments; Fig. 5a–e and caption; corresponding Results